RxDoctor Payments Data

Catherine Smith, MD

Internal Medicine · San Francisco, CANPI 1164471488

Payments from drug & device makers

$559,245in general payments, 2019–2025

Across 72 payments — averaging $7767.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$331K
  • Bristol Myers Squibb$97K
  • Astellas Pharma Global Development$51K
  • Genentech, Inc.$37K
  • Daiichi Sankyo Company LTD$18K
  • Astellas Pharma Inc$15K
  • plus $9K from 6 others
$8,828in research payments, 2019–2025

Across 30 payments — averaging $294.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$9K

What the payments were for

  • Consulting fees$20,08123%
  • Speaking & faculty fees$3,0703%
  • Grants$36,93242%
  • Travel & lodging$27,31631%
  • Food & beverage$9731%
  • Education$600%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$559,245 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$173,995
Medicare patients
107
Services billed
3,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate62$1,170,999
TasignaNilotinib Hcl24$492,954
ScemblixAsciminib Hydrochloride15$322,264
InqoviDecitabine/Cedazuridine27$203,458
BosulifBosutinib11$85,182
SprycelDasatinib13$76,291
PegasysPeginterferon Alfa-2a16$68,700
ProcritEpoetin Alfa11$46,282
Posaconazole16$25,130
XareltoRivaroxaban12$6,691
Anagrelide Hcl11$2,798
Hydroxyurea53$2,152
Ursodiol13$895
Acyclovir37$554
Dexamethasone16$359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerBosulif$40$85,18211 claims
Genentech, Inc.Pegasys$36,959$68,70016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →